BR112015029386A2 - uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer - Google Patents

uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer

Info

Publication number
BR112015029386A2
BR112015029386A2 BR112015029386A BR112015029386A BR112015029386A2 BR 112015029386 A2 BR112015029386 A2 BR 112015029386A2 BR 112015029386 A BR112015029386 A BR 112015029386A BR 112015029386 A BR112015029386 A BR 112015029386A BR 112015029386 A2 BR112015029386 A2 BR 112015029386A2
Authority
BR
Brazil
Prior art keywords
lenvatinib
eribulin
combination therapy
cancer treatment
cancer
Prior art date
Application number
BR112015029386A
Other languages
English (en)
Other versions
BR112015029386B1 (pt
BR112015029386A8 (pt
Inventor
Wu Jiayi
Nomoto Kenichi
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112015029386A2 publication Critical patent/BR112015029386A2/pt
Publication of BR112015029386A8 publication Critical patent/BR112015029386A8/pt
Publication of BR112015029386B1 publication Critical patent/BR112015029386B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

resumo patente de invenção: "uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer". a presente invenção refere-se aos métodos e composições para uso no tratamento de doenças associadas à proliferação celular excessiva, tal como câncer.
BR112015029386-7A 2013-06-26 2014-06-26 Uso de eribulina e lenvatinibe como terapia de combinação e kit BR112015029386B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361839542P 2013-06-26 2013-06-26
US61/839,542 2013-06-26
PCT/JP2014/067723 WO2014208774A1 (en) 2013-06-26 2014-06-26 Use of eribulin and lenvatinib as combination therapy for treatment of cancer

Publications (3)

Publication Number Publication Date
BR112015029386A2 true BR112015029386A2 (pt) 2017-07-25
BR112015029386A8 BR112015029386A8 (pt) 2020-03-17
BR112015029386B1 BR112015029386B1 (pt) 2023-11-14

Family

ID=51210708

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029386-7A BR112015029386B1 (pt) 2013-06-26 2014-06-26 Uso de eribulina e lenvatinibe como terapia de combinação e kit

Country Status (12)

Country Link
US (1) US9549922B2 (pt)
EP (1) EP3013335B1 (pt)
JP (1) JP6404242B2 (pt)
KR (1) KR102265952B1 (pt)
CN (1) CN105338977B (pt)
AU (1) AU2014299699B2 (pt)
BR (1) BR112015029386B1 (pt)
CA (1) CA2915005C (pt)
ES (1) ES2705698T3 (pt)
IL (1) IL242386B (pt)
RU (1) RU2672585C2 (pt)
WO (1) WO2014208774A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2415470T (pt) 2009-03-30 2016-08-31 Eisai R&D Man Co Ltd Composição de lipossomas
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
MX2017001980A (es) 2014-08-28 2017-05-04 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y metodo para su produccion.
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
EP3265122B1 (en) 2015-03-04 2022-05-04 Merck Sharp & Dohme Corp. Combination of pembrolizumab and eribulin for treating triple-negative breast cancer
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
MX2017015896A (es) 2015-06-16 2018-08-09 Eisai R&D Man Co Ltd Agente anticancerigeno.
JP7015237B2 (ja) * 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
CN105832732A (zh) * 2016-05-30 2016-08-10 青岛云天生物技术有限公司 一种用于胃癌治疗的药物组合物及其应用
EP3564243B1 (en) * 2017-01-02 2022-11-09 Yonsung Fine Chemical Co., Ltd. Production intermediate of eribulin mesylate, and method for producing same
BR112019014127A2 (pt) * 2017-02-08 2020-02-11 Eisai R&D Management Co., Ltd. Composição farmacêutica para tratamento de tumores
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
CN107973804B (zh) * 2017-11-29 2020-07-03 戊言医药科技（上海）有限公司 艾瑞布林中间体的合成方法
CN111787922A (zh) * 2018-01-10 2020-10-16 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
CN109793736A (zh) * 2019-01-31 2019-05-24 徐州医科大学 一种乐伐替尼在制备自然杀伤细胞激动剂中的应用
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN114028394A (zh) * 2021-05-21 2022-02-11 中山大学 低剂量仑伐替尼在制备治疗肝癌的药物中的用途
WO2023018675A1 (en) * 2021-08-10 2023-02-16 Merck Sharp & Dohme Llc A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277873B1 (en) 1998-06-17 2012-05-30 Eisai R&D Management Co., Ltd. Intermediate compound for the preparation of halichondrin analogs
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
WO2003074045A1 (fr) 2002-03-05 2003-09-12 Eisai Co., Ltd. Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
SI1698623T1 (sl) 2003-12-25 2015-07-31 Eisai R&D Management Co., Ltd. Kristal soli 4-(3-kloro -4-(ciklopropilaminokarbonil)amino-fenoksi)-7- metoksi-6-kinolinkarboksamida ali njihov solvat in postopek njune proizvodnje
JP5226304B2 (ja) * 2004-06-03 2013-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の調製用中間体
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007052850A1 (ja) 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
CN101616671A (zh) 2007-01-19 2009-12-30 卫材R&D管理有限公司 胰腺癌治疗用组合物
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
ES2670423T3 (es) * 2007-07-25 2018-05-30 Eisai R&D Management Co., Ltd. Inhibidores de multicinasas para uso en el tratamiento de cáncer
CN101883763B (zh) 2007-10-03 2016-04-20 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
KR101506062B1 (ko) 2008-01-29 2015-03-25 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 저해 물질과 탁산의 병용
BR112012018232B8 (pt) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
US20120077837A1 (en) 2010-09-24 2012-03-29 Eisai R&D Management Co., Ltd. Anti-tumor agent
WO2012119077A1 (en) * 2011-03-02 2012-09-07 Morphotek Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer
JP2014509515A (ja) * 2011-03-18 2014-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンに対する応答を予測するための方法及び組成物
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012154935A1 (en) 2011-05-12 2012-11-15 Eisai R&D Management Co., Ltd. Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof
US9945862B2 (en) * 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2015225436A1 (en) 2014-03-03 2016-09-08 Eisai R&D Management Co., Ltd. Use of eribulin and mTOR inhibitors as combination therapy for the treatment of cancer
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
KR20170039096A (ko) 2014-05-28 2017-04-10 에자이 알앤드디 매니지먼트 가부시키가이샤 암의 치료에 있어서 에리불린의 용도
JP6644479B2 (ja) 2014-06-24 2020-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用

Also Published As

Publication number Publication date
CN105338977A (zh) 2016-02-17
BR112015029386B1 (pt) 2023-11-14
WO2014208774A1 (en) 2014-12-31
JP6404242B2 (ja) 2018-10-10
KR102265952B1 (ko) 2021-06-16
AU2014299699A1 (en) 2015-12-10
ES2705698T3 (es) 2019-03-26
CA2915005C (en) 2021-12-28
CN105338977B (zh) 2018-10-16
KR20160023816A (ko) 2016-03-03
AU2014299699B2 (en) 2019-10-10
RU2672585C2 (ru) 2018-11-16
BR112015029386A8 (pt) 2020-03-17
CA2915005A1 (en) 2014-12-31
JP2016528162A (ja) 2016-09-15
RU2016102158A (ru) 2017-07-31
US9549922B2 (en) 2017-01-24
IL242386B (en) 2019-06-30
EP3013335A1 (en) 2016-05-04
EP3013335B1 (en) 2018-11-07
US20150005343A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
GT201500248A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MX2017013321A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX364486B (es) Derivados de piridazinona-amidas.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CO7180225A2 (es) Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib
WO2015009726A3 (en) Medical uses of cd38 agonists
PH12015502161A1 (en) Therapeutic compounds and compositions
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
EA201591925A1 (ru) Терапевтические композиции и их применение
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
CR20140367A (es) Inhibidores de iap
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
MX2017009608A (es) Compuestos anticancerigenos.
PH12015502564B1 (en) Pyridone derivatives for the treatment of viral infections and further diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2014, OBSERVADAS AS CONDICOES LEGAIS